PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. MU
4. SPY
5. ACN
6. IBM
7. META
8. PFE
9. TSLA
10. DPZ

Go back to PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval
(NASDAQ: PRCT) Delayed: 20.27 -0.79 (3.75%)
Previous Close $21.06    52 Week High $ 
Open $21.26    52 Week Low $ 
Day High $21.50    P/E N/A 
Day Low $19.92    EPS $ 
Volume 754,383